INCIDENCE AND MANAGEMENT OF CARDIAC AND PULMONARY ADVERSE EVENTS FOLLOWING SINGLE-AGENT CARFILZOMIB TREATMENT IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Richards, Tiffany [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ONCOLOGY NURSING FORUM | 2014年 / 41卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
151
引用
收藏
页码：E144 / E145
页数：2
相关论文
共 50 条
  • [41] The Speed of Response to Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: An Exploratory Analysis of Results From 2 Multicenter Phase 2 Clinical Trials
    Wang, Luhua
    Siegel, David S.
    Jakubowiak, Andrzej J.
    Wong, Alvin F.
    Dixon, Sandra
    Renau, Thomas E.
    Vij, Ravi
    BLOOD, 2011, 118 (21) : 1698 - 1698
  • [42] A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
    Sborov, Douglas W.
    Nuovo, Gerard J.
    Stiff, Andrew
    Mace, Thomas
    Lesinski, Gregory B.
    Benson, Don M., Jr.
    Efebera, Yvonne A.
    Rosko, Ashley E.
    Pichiorri, Flavia
    Grever, Michael R.
    Hofmeister, Craig C.
    CLINICAL CANCER RESEARCH, 2014, 20 (23) : 5946 - 5955
  • [43] An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma
    Prince, H. Miles
    Schenkel, Brad
    Mileshkin, Linda
    LEUKEMIA & LYMPHOMA, 2007, 48 (01) : 46 - 55
  • [44] Efficacy of single-agent bortezomib versus thalidomide in patients with relapsed or refractory multiple myeloma: A systematic review.
    Prince, M
    Adena, M
    Smith, DK
    Hertel, J
    BLOOD, 2005, 106 (11) : 373B - 373B
  • [45] Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients
    Hojholt, Karen Louise
    Gregersen, Henrik
    Szabo, Agoston Gyula
    Klausen, Tobias Wirenfeldt
    Levring, Mette Boegh
    Preiss, Birgitte
    Helleberg, Carsten
    Breinholt, Marie Fredslund
    Hermansen, Emil
    Rahbek Gjerdrum, Lise Mette
    Bonlokke, Soren Thorgaard
    Nielsen, Katrine
    Kjeldsen, Eigil
    Iversen, Katrine Fladeland
    Teodorescu, Elena Manuela
    Kurt, Eva
    Strandholdt, Casper
    Andersen, Mette Klarskov
    Vangsted, Annette Juul
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (04) : 521 - 528
  • [46] Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma
    Catamero, Donna
    Ray, Chloe
    Purcell, Kiah
    Leahey, Sheryl
    Esler, Elaine
    Rogers, Stephanie
    Hefner, Kayla
    O'Rourke, Lisa
    Gray, Kathleen
    Tolbert, Jaszianne
    Renaud, Thomas
    Patel, Saurabh
    Hannemann, Linda
    Shenoy, Samantha
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (05)
  • [47] Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
    Jayaweera, Shansa Pranami E.
    Wanigasinghe Kanakanamge, Sacheela Prasadi
    Rajalingam, Dharshika
    Silva, Gayathri N.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [48] Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma
    Nadeem, Omar
    Ailawadhi, Sikander
    Khouri, Jack
    Williams, Louis
    Catamero, Donna
    Maples, Kathryn
    Berdeja, Jesus
    CANCERS, 2024, 16 (05)
  • [49] A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma
    Franken, B.
    van de Donk, N. W. C. J.
    Cloos, J. C.
    Zweegman, S.
    Lokhorst, H. M.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (06) : 330 - 344
  • [50] Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal
    Usmani, S. Z.
    Hoering, A.
    LEUKEMIA, 2013, 27 (12) : 2269 - 2271
12345